The study will look at how two different versions of semaglutide reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different versions. Participants will get both versions of semaglutide. The order in which participants receive the versions is decided by chance. Participants will get the medicines as an injection under the skin of the belly with the use of a pen-injector. The study will last for about 11 to 17 weeks. Participants will have 27 visits with the study doctor. At 2 visits, participants will stay in the clinic for 4 days and 3 nights. Participants may have to stop the study if the study doctor thinks that there are risks for their health. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
28
Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks
Novo Nordisk Investigational Site
Neuss, Germany
Area under the semaglutide plasma concentration curve from 0 to tz
h\*nmol/L
Time frame: 0-840 hours
Maximum semaglutide plasma concentration
nmol/L
Time frame: 0-840 hours
Area under the semaglutide plasma concentration curve
h\*nmol/L
Time frame: 0-840 hours
Time to Cmax for semaglutide
h
Time frame: 0-840 hours
Terminal elimination half-life
h
Time frame: 0-840 hours
Total apparent clearance of semaglutide
L/h
Time frame: 0-840 hours
Apparent volume of distribution of semaglutide
L
Time frame: 0-840 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.